Pharmaceutical company Breckenridge Pharmaceutical Inc reported on Tuesday the receipt of US Food and Drug Administration final approval for an Abbreviated New Drug Application for Erlotinib Hydrochloride Tablets (generic Tarceva) in EQ 25mg base, EQ 100mg base and EQ 150mg base strengths for the treatment of non-small cell lung cancer and pancreatic cancer.
The Abbreviated New Drug Application of Erlotinib Hydrochloride Tablets is reportedly held by Natco Pharma Limited and developed in collaboration with MEDIK Ltd.
Under Breckenridge's marketing, sale and distribution agreement, the Erlotinib Hydrochloride Tablets will be manufactured and supplied by Natco and Breckenridge plans to launch the product immediately.
According to industry sales data, Tarceva and its therapeutic equivalents generated annual sales of approximately USD145m in the year ended 30 September 2019.
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
EQT agrees to acquire majority stake in Adalvo
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
Avera joins Civica to help maintain drug supplies
Apotex launches generic version of Tasigna in US market
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets